Rizatriptan, is a triptan medication specifically indicated for acute treatment of migraine headaches with or without aura. It functions as a selective agonist at serotonin 5-HT1B/1D receptors, helping to constrict blood vessels in the brain and block pain pathways by inhibiting release of neuropeptides like calcitonin gene-related peptide from trigeminal nerve sensory neurons. Contraindicated in those with cardiovascular disease due to vasoconstrictive effects, it interacts notably with propranolol via MAO-A enzyme pathways.